-
1 Comment
Karo Pharma AB (publ) is currently in a long term uptrend where the price is trading 4.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.0.
Karo Pharma AB (publ)'s total revenue rose by 11.1% to $721M since the same quarter in the previous year.
Its net income has dropped by 17.6% to $-27M since the same quarter in the previous year.
Finally, its free cash flow grew by 263.9% to $73M since the same quarter in the previous year.
Based on the above factors, Karo Pharma AB (publ) gets an overall score of 4/5.
Exchange | F |
---|---|
CurrencyCode | EUR |
ISIN | None |
Sector | |
Industry |
PE Ratio | 10.23 |
---|---|
Target Price | None |
Dividend Yield | 0.0% |
Beta | 0.09 |
Market Cap | 2B |
Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. It offers skin health products under the Remescar, Locobase, Decubal, and indy beauty brand names; intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brand names; and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. The company also provides pain, cough, and cold products under the Paracet, Ibux, Mollipect, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Lithionit brands; and wellness products under the nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare brands. It sells its products in approximately 90 countries with Europe and the Nordic region markets through direct sales organizations and a network of distributors, as well as online. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was incorporated in 1987 and is headquartered in Stockholm, Sweden.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for KA6N.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025